- Details
- Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted approach of erdafitinib, emphasizing its efficacy in hitting specific genetic alterations, particularly FGFR3/2 mutations, prevalent in 15-20% of metastatic bladder tumors. Highlighting the drug's journey...
|
- Details
- Sam Chang interviews Michiel Van der Heijden about the results of the EV-302 trial, comparing enfortumab vedotin plus pembrolizumab (EVP) against chemotherapy in previously untreated advanced urothelial cancer patients. Dr. Van der Heijden outlines the trial's structure and its remarkable findings, noting the hazard ratios for progression-free and overall survival rates that favor EVP. He delves i...
|
- Details
- Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with pembrolizumab versus observation. However, overall survival data is still maturing. Patients who received pembrolizumab had a median disease-free survival of 29 months versus 14 months for the observation...
|
- Details
- Amanda Nizam presents findings from the UNITE study at GU ASCO 2024, exploring enfortumab vedotin's (EV) efficacy in patients with advanced urothelial carcinoma post-platinum-based chemotherapy and maintenance avelumab. This retrospective analysis, involving 633 patients across 16 US sites, reveals that EV's outcomes are consistent with previous trials, even after maintenance avelumab. Despite exp...
|
- Details
- Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a platinum drug shortage. Despite setbacks, efforts are underway to increase patient enrollment, with assistance from Canadian colleagues. The conversation with Dr. Sam Chang reveals no safety concerns with the combination of TKI and immuno...
|
- Details
- Hiten Patel discusses his team’s study on the use of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. The research, motivated by low utilization rates observed in practice, aimed to understand elective and eligibility factors affecting the treatment's application. Analyzing data from Loyola University Medical Center, the study found that while 40% of patients...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group on clinical trial designs for bladder cancer. They focus on locally advanced and metastatic urothelial carcinoma, emphasizing the need for new treatments and rational trial designs. The panel, comprising 25 multidisciplinary experts, aims to guide late-pha...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group for muscle-invasive bladder cancer (MIBC) clinical trial design. Published in the Journal of Clinical Oncology with Dr. Ashish Kamat as lead author, these guidelines aim to advance treatment for urothelial carcinoma. The 25-member panel, including a patien...
|
- Details
- Guru Sonpavde and Matt Galsky delve into the CheckMate 901 study and its implications for advanced bladder cancer treatment. Dr. Sonpavde outlines the study's design, focusing on comparing gemcitabine cisplatin with and without nivolumab in cisplatin-eligible patients. He highlights the study's backdrop, noting previous trials and the potential immunogenic superiority of cisplatin. Dr. Galsky pres...
|
- Details
- Alicia Morgans hosts Guru Sonpavde and Bradley McGregor to discuss the DAD trial, which uniquely combines enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates (ADCs), for advanced urothelial carcinoma. Dr. Sonpavde highlights the distinct mechanisms and non-overlapping toxicities of these drugs. Funded by Gilead, the trial adopts a Phase I BOIN design, starting with lower dos...
|
